Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Cell & gene therapy

Research Field Cell & gene therapy

It’s a Drug’s Life

| Geoffrey Potjewyd | 5 min read

Many drugs are applied to the eye, yet we have little to no quantitative data on ocular drug metabolism – until now…

Research Field Cell & gene therapy

(Fibro)Blast-off!

| Hamid Khoja | 4 min read

In regenerative medicines and therapeutics, fibroblasts can offer significant advantages over stem cells, says Hamid Khoja

Disease Area Cell & gene therapy

The Genomic Revolution

| Stephanie Sutton

Can genomic medicine usher in a new era of curative treatments for neurological diseases? Experts from Sangamo give their views

Disease Area Cancer

Resolve Cancer

| Sponsored by 10x Genomics

Unravel the complexity of cancer biology and reveal insights to advance human health

Research Field Cancer

“Curing Cancer? That’s Cute”

| James Strachan

Cell and gene therapies are now considered mainstream therapeutic modalities – with revolutionary potential. But that hasn’t always been the case…

Research Field Pain & critical care

An Osteoarthritic Odyssey

Sitting Down With… Mike Clayman, CEO of Flexion Therapeutics, Inc., Burlington, Massachusetts, USA.

Research Field Cell & gene therapy

A Fighting Chance

| Neil Ebenezer

A new technique shows promising results for patients with sight loss from Leber congenital amaurosis

Research Field Cell & gene therapy

Perusing the Pipeline

| James Strachan

With cell and gene therapies being all the rage, we take a peek at some of the advanced therapies coming down the pipe.

Research Field Cell & gene therapy

Swimming against the nucleotides

| James Bainbridge

Tomorrow’s cures for retinopathies will likely include advanced gene and cell therapies delivered by precision surgery.

Research Field Cell & gene therapy

Now For the High-Hanging Fruit

| Miguel Forte

We should be thrilled with the success of the approved CD-19 CAR-T therapies. But the field is still young, and we are only scratching the surface.


Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register